Pharma Audits FDA Draft Guidance on Responding to Form 483 Observations: A Practical Guide for CGMP Sites Read More » June 18, 2026 No Comments
Pharmacovigilance Services FDA’s New Overseas Inspection Approach: What Pharma Sites Need to Know Read More » June 16, 2026 No Comments
Pharmacovigilance Services EMA and FDA Issue Joint Principles on AI in Medicine Development: What It Means for PV Teams Read More » June 11, 2026 No Comments
Pharma Audits GDP 2026: Understanding MHRA, DSCSA, and Global Traceability Requirements Read More » June 9, 2026 No Comments
GVP Audits Root Cause Analysis Tools for GxP CAPA: When to Use Ishikawa, 5-Why and Fault Tree Analysis Read More » June 4, 2026 No Comments
Pharma Audits PSMF Maintenance Checklist: What Needs Updating After a Licence Variation, Product Transfer or MAH Change Read More » June 2, 2026 No Comments
Pharmacovigilance Services CE Mark vs National Device Approvals: How Global Medical Device Manufacturers Should Plan Their Compliance Strategy in 2026 Read More » May 28, 2026 No Comments
Pharma Audits EMA, FDA and MHRA GMP Annex Revisions 2026- 2028: What Every Pharma QA Team Must Prepare For Read More » May 26, 2026 No Comments
Pharma Audits GMP Mock Inspection for Pharmaceutical Manufacturers: What Global Regulators Check That Internal Teams Miss Read More » May 21, 2026 No Comments
GVP Audits How to Respond to a Regulatory Deficiency Letter: A Step-by-Step CAPA Guide for Pharmaceutical Sites Read More » May 19, 2026 No Comments